ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials
Recent deals have been driven more by tax strategies than therapeutic synergies.
Morningstar StockInvestor editor Matt Coffina highlights three of the highest-quality companies we cover.
The top contract research organizations have opportunities to gain share in a rapidly growing industry.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.
Obamacare will benefit some sectors more than others, but poor economy and pricing pressures are the biggest challenges most health-care firms must face.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...